Moore Capital Management’s Prime Medicine PRME Stock Holding History

Moore Capital Management’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.84M	Hold	500,000	–	–	0.03%	419
2026 Q1	$1.74M	Hold	500,000	–	–	0.04%	308
2025 Q4	$1.74M	Hold	500,000	–	–	0.03%	399
2025 Q3	$2.77M	Hold	500,000	–	–	0.04%	321
2025 Q2	$1.24M	Hold	500,000	–	–	0.02%	357
2025 Q1	$995K	Hold	500,000	–	–	0.02%	319
2024 Q4	$1.46M	Hold	500,000	–	–	0.02%	349
2024 Q3	$1.94M	Hold	500,000	–	–	0.04%	307
2024 Q2	$2.57M	Hold	500,000	–	–	0.04%	255
2024 Q1	$3.5M	Buy	+500,000	New	+$3.79M	0.06%	232
2023 Q4	–	Sell	-446,733	Closed	-$4.26M	–	520
2023 Q3	$4.26M	Hold	446,733	–	–	0.08%	189
2023 Q2	$6.54M	Sell	446,733 -53,267	-11%	-$744K	0.11%	141
2023 Q1	$6.15M	Hold	500,000	–	–	0.13%	125
2022 Q4	$9.29M	Buy	+500,000	New	+$9.03M	0.22%	86

Other funds holding PRME

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Moore Capital Management's PRME Position: Q2 2026 in Review

Moore Capital Management held its Prime Medicine (PRME) position steady in Q2 2026 at 500,000 shares worth $1.84M. The position accounts for 0.03% of the portfolio, ranked #419.

Moore Capital Management first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $9.29M in Q4 2022. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

Moore Capital Management held 500,000 shares of Prime Medicine worth $1.84M as of Q2 2026.
Moore Capital Management left its Prime Medicine share count unchanged in Q2 2026.
Prime Medicine made up 0.03% of Moore Capital Management's portfolio in Q2 2026, its #419 holding.
Moore Capital Management first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
Moore Capital Management's Prime Medicine position peaked at $9.29M in Q4 2022.
188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.